common side effects of glp-1 receptor agonists Glucagon-like Receptor-1 for obesity: Weight loss outcomes, tolerability, effects, and risks Ozempic (Semaglutide): GLP-1 receptor agonist

Although stringent screening protocols are implemented, caution remains essential

The SELECT trial reported a 20% reduction in major adverse cardiovascular events with semaglutide versus placebo in patients with overweight/obesity and established cardiovascular disease, without diabetes [34] [35]

Calcein/PI staining revealed that, compared with oe-ILF3 alone, oe-ILF3+simvastatin enhanced the cytotoxicity of simvastatin in GC cells (Figure S2F, G)

However, tetracycline, minocycline, dapsone, and topical corticosteroids are also mentioned as treatment options (234, 235, 237)

Goldstein AM, Bale SJ, Peck GL, DiGiovanna JJ

El futuro del manejo del envejecimiento cutneo parece ser el tratamiento con agentes senolticos o senomrficos dirigidos especficamente contra clulas cutneas senescentes